Topic 16 · Everything else
Gene Therapy (Future Direction)
Mouse data, and as of July 2026 horse data. No human joint trial — and TG-C missed both co-primary endpoints in a 531-patient Phase 3.
Current Status
→ Gene therapy = giving cells new instructions. Delivers genes that tell cells to produce more cartilage proteins. Still experimental for ankle - most research in lab animals - but represents the future of repair.
Gene therapy for cartilage is advancing but not yet clinically available for ankle OLT [112]:
- Most trials use MSCs (36%), followed by PRP (20%) [113]
- Recombinant AAV vectors delivering FGF-2, IGF-1, SOX9 show promise in animal models
- Allogeneic transduced chondrocytes in early clinical trials for OA
Mayo Clinic Phase 1 Trial
A recycled cartilage auto/allo implantation technique is being studied [114]:
- Combines 10-20% autologous chondrons with 80-90% allogenic MSCs
- Under FDA IND status at Mayo Clinic
- Represents future direction for cartilage repair
Status: Experimental. Not available for routine clinical use in 2025.